Recent Analysts’ Ratings Updates for DaVita (DVA)

DaVita (NYSE: DVA) recently received a number of ratings updates from brokerages and research firms:

• 5/11/2026 – DaVita had its price target raised by TD Cowen from $144.00 to $201.00. They now have a “hold” rating on the stock.
• 5/11/2026 – DaVita had its price target raised by TD Cowen from $144.00 to $201.00. They now have a “hold” rating on the stock.
• 5/8/2026 – DaVita had its price target raised by Truist Financial Corporation from $158.00 to $205.00. They now have a “hold” rating on the stock.
• 5/7/2026 – DaVita had its price target raised by Barclays PLC from $158.00 to $194.00. They now have an “equal weight” rating on the stock.
• 5/7/2026 – DaVita was upgraded by Zacks Research from “hold” to “strong-buy”.
• 5/7/2026 – DaVita had its price target raised by UBS Group AG from $190.00 to $235.00. They now have a “buy” rating on the stock.
• 5/6/2026 – DaVita was upgraded by Deutsche Bank Aktiengesellschaft from “hold” to “buy”. They now have a $220.00 price target on the stock, up from $126.00.
• 4/6/2026 – DaVita was downgraded by Zacks Research from “strong-buy” to “hold”.

Insider Buying and Selling at DaVita

In other news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.50% of the company’s stock.

Get DaVita Inc alerts:

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Read More

• Five stocks we like better than DaVita
• Viking Sails to All-Time Highs—Fundamentals Signal More to Come
• Datavalut Gains Traction: 5 Reasons to Sell Now
• TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
• The Power Grid Is Dying—Is It Time to Buy Its Replacement?

Receive News & Ratings for DaVita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita Inc and related companies with MarketBeat.com's FREE daily email newsletter.